This article presents information on two studies regarding the competing risks of colorectal cancer and heart disease. The potential for prevention of colorectal cancer were somewhat overstated while the risks associated with heart problems were minimized. Lumping all polyps together without mention of the percentage that are likely to go on to develop into malignancies is a disservice because it exaggerates the cancer risk. In that regard, this story is an example of disease mongering because it fails to make the distinction between colonic polyps and cancerous polyps. The majority of polyps found and removed during the course of colonoscopy are neither malignant nor invasive.
There is no mention of the costs of treatment.
The heart related side effects observed in the two studies are provided in absolute frame (3.4% vs. 2.5% in the first study; 7.5% vs. 4.6% in the second study); the risk of developing polyps was presented as 60% vs. less than 50% in the first study; 49% vs. 34% in the second study). Early in the article, the reduction in polyps is presented as a 33% to 45% reduction. Only the 33% reduction (second study) can be calculated from the information provided. The 45% reduction is found in the press release on the study from the meeting at which it was presented.
The heart-related side effects, listed as heart attacks, stroke, and other serious heart-related problems, are mentioned. No mention was made of the gastrointestinal, renal and hemorrhagic events associated with treatment.
This article reported on results from two randomized, double-blind trials examining the potential for prevention of colorectal adenoma in patients with a history of colorectal neoplasia.
This story is an example of disease mongering because it fails to make the distinction between colonic polyps and cancerous polyps. The majority of polyps found and removed during the course of colonoscopy are neither malignant nor invasive.
No attempt appears to have been made to contact individuals not associated directly with the two studies mentioned, other than a spokesperson from the National Cancer Institute, the agency that funded one of the studies presented.
No other approaches for colorectal adenocarcinoma prevention were presented.
Article states that Celebrex is the only cox-2 inhibitor still on the market. While Celebrex is the only FDA approved cox-2 inhibitor sold, there are a number of approved NSAID medications available which, while not specific for cox-2, inhibit both cox-1 and cox-2.
The proposed use of cycloxygenase inhibition as a preventative treatment for people with mutation in the APC gene and thus at increased risk for colorectal adenoma is not new.
We can’t be sure that the story relied solely or largely on a news releae, but the article did appear to use the press release supplied by the American Association for Cancer Research as a source of information for this story.
Systematic, Criteria-Driven
I miss @HealthNewsRevu popping up in my feed. Loved seeing this one today.
https://www.healthnewsreview.org/2021/06/zombie-health-care-news/
#healthcare #journalism #ethics #conflictofinterest
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like